Phaseline

Targets › IMPA1

IMPA1 (Inositol monophosphatase 1): drug programs, companies and trials

1 program from 1 company in 9 trials: 3 Phase 1, 3 Phase 4, 2 Phase 2, 1 Phase 3; Neurology, Oncology, Other; next expected readout Dec 2026.

Phosphatase involved in the dephosphorylation of myo-inositol monophosphates to generate myo-inositol. Is also able to dephosphorylate scyllo-inositol-phosphate, myo-inositol 1,4-diphosphate, scyllo-inositol-1,3-diphosphate and scyllo-inositol-1,4-diphosphate. (UniProt, P29218)

Open in Phaseline: the race on IMPA1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Alzamend NeuroLithium Carbonate (AL001)
Inositol-1(or 4)-monophosphatase 1 inhibitor; Glycogen synthase kinase-3 inhibitor
IMPA1, GSK3A, GSK3BPhase 1Bipolar I Disorder; Healthy; Bipolar II Disorder; Depression, Bipolar …Dec 2026

Conditions

Bipolar I Disorder (1) Healthy (1) Bipolar II Disorder (1) Depression, Bipolar (1) Bipolar Depression (1) Cornelia De Lange Syndrome (1) Cognitive Impairment (1) Parkinson Disease (1) Proven Pathogenic or Probably Pathogenic TBR1 Variant (1)

Modalities

small molecule (1)

Companies

Alzamend Neuro (1)

Related targets

GSK3A (1) GSK3B (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.